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MicroRNAs (miRNAs) are small noncoding regulatory RNAs that regulate gene expression post-transcriptionally by
either inhibiting protein translation or degrading target mRNAs. The differential expression profiles of miRNAs in
different types of cancers and in the multi-step process of tumor progression indicate that miRNAs are involved in
tumor onset, growth and progression. Metastasis is the most common cause of cancer-related mortality. Current
evidence demonstrates that aberrant miRNA expression promotes or inhibits tumor metastasis by modulating the
expression of numerous target genes. Therefore, the identification of metastasis-related miRNAs and a better
understanding of the complex functions of miRNAs in tumor metastasis will provide potential diagnostic and
prognostic biomarkers, as well as therapeutic targets for clinical application. Here, we review the functions of
miRNAs in the control of multiple steps of tumor metastasis.
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Metastasis remains a major challenge for the clinical
management and prognosis of patients with cancer. As
the most common cause of cancer-related mortality,
metastasis involves several continuous steps through
which cancer cells disseminate and spread from a primary
tumor to distant sites, forming secondary tumors in other
organs and tissues [1–3]. Recent studies have provided ex-
citing new insights into the molecular mechanisms of
tumor metastasis; however, research on the functions and
mechanisms of microRNAs (miRNAs) in metastasis has
only recently begun.
miRNAs are highly conserved, endogenous noncoding
RNAs that have been shown to regulate distinct cellular
processes by interfering with protein expression at the
post-translational level. Specifically, miRNAs modulate
gene expression by binding to the 3’-untranslated-region
(UTR) of target mRNAs, which have complete or partial
complementarity with their seed region. This results in* Correspondence: wxm@xmzsh.com; oygldz@xmu.edu.cn
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target mRNAs and the subsequent downregulation of
protein expression. Current evidence has demonstrated
that many miRNAs that have normal functions in the
modulation of physiological processes are deregulated
in various pathological processes, including tumor on-
set, growth and metastasis [4–6]. A single miRNA can
function as an oncogene or as a tumor suppressor gene
to silence the expression of many target genes and
thereby remodel the expression profile of cells. Thus,
specific miRNAs can function as promoters or suppres-
sors of metastatic progression and coordinately inhibit
numerous target genes in tumor metastasis. Aberrant
miRNA expression profile during multi-step metastatic
processes is a common characteristic of tumor metastasis
[7, 8]. It was recently discovered that secreted miRNAs
have also been found in the serum and other body fluids
of individuals with cancer [9, 10]. Acting in a manner
consistent with their primary roles, secretory miRNAs
also act as translational inhibitors in recipient cells,
which indicates that secretory miRNAs can regulate
cellular processes at distant sites during the tumor
metastatic cascade. Therefore, miRNAs may be good
targets for the modulation of multiple steps of the
metastatic cascade. In this review, we focus on the roles
of miRNAs in the regulation of tumor metastasis, andicle distributed under the terms of the Creative Commons Attribution License
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prognostic biomarkers and therapeutic targets for
tumor metastasis.
Functions of miRNAs in the tumor metastatic cascade
miRNAs and local invasion
Some tumors rarely disseminate to distant target sites al-
though they are locally invasive, whereas other tumors
are highly aggressive and establish metastatic lesions at
secondary sites at a high frequency. To migrate to sec-
ondary sites and to flourish in those sites, disseminated
tumor cells (DTCs) that have detached from the primary
tumor microenvironment must survive a series of steps
termed the metastatic cascade. Cancer cell detachment,
migration and invasion are early steps in the invasion
and metastatic cascade. Current evidence demonstrates
that miRNAs play critical roles in tumor cell invasion.
miR-10b, which promotes cell migration and invasion,
has been identified as a metastasis-promoting miRNA in
breast cancer [11]. The silencing of miR-10b reduces
mesenchymal subtype-like glioma cell invasion through
the suppression of TP53, PAX6, NOTCH1 and HOXD10
[12]. The miR-17-92 cluster is often amplified in cancers.
The miR-17-92 cluster member miR-19a/b is highly
expressed in gastric cancer tissues and is significantly
associated with gastric cancer metastasis. miR-19a/b
promotes the migration, invasion and metastasis of gastric
cancer cells by targeting MXD1, an antagonist of c-Myc
[13]. miR-135b expression is also increased in invasive
non-small-cell lung cancer cells. miR-135b promotes cell
migration and invasion in vitro and increases cancer me-
tastasis in vivo via the regulation of the Hippo pathway
[14]. miR-362-5p is highly expressed in hepatocellular car-
cinomas (HCCs) and correlates with HCC progression.
The inhibition of miR-362-5p in HCC cells suppresses cell
proliferation, migration and invasion in vitro and tumor
growth and metastasis in vivo [15].
In contrast, some miRNAs are negative regulators of
cell invasion. miR-34a and miR-34c are significantly
downregulated in metastatic breast cancer. The restor-
ation of miR-34a/c in breast cancer cell lines inhibits cell
migration and invasion in vitro and reduces distal pul-
monary metastasis in vivo by directly targeting Fra-1
[16]. Androgen-regulated miR-135a inhibits prostate the
migration and invasion of cancer cells directly through
its downstream targets, ROCK1 and ROCK2 [17].
HMGA1 activates miR-137 transcription by binding to
the promoter of miR-137 in colorectal cancer cells,
which reduces the level of FMNL2, a downstream target
of miR-137. The ectopic expression of miR-137 reduces
the invasiveness of colorectal cancer cells [18]. miR-145
attenuates gastric cancer cell migratory and invasive
abilities in vitro by targeting N-cadherin (CDH2). Assays
to detect experimental and spontaneous metastasisfurther confirmed that miR-145 suppresses the metastatic
cascade in vivo [19]. The overexpression of miR-145
inhibits the invasiveness and metastasis of neuroblastoma
cells by targeting HIF-2α [20]. miR-1 expression is con-
sistently downregulated in primary human prostate tu-
mors and is reduced even more in distant metastases.
As a prostate cancer suppressor, miR-1 affects the cellular
organization of F-actin and impairs tumor cell invasion
and the formation of filopodia [21]. These findings indi-
cate that miRNAs play critical roles in the regulation of
local invasion by cancer cells.
The breakdown and remodeling of the extracellular
matrix are critical steps in cancer cell invasion. Tenascin
C and other matricellular proteins, such as periostin and
osteopontin, play important roles in remodeling the
tumor metastatic microenvironment [22, 23]. The loss of
miR-335 expression is related to poor distal metastasis-
free survival of patients with breast cancer. The restor-
ation of miR-335 expression suppresses cell migration,
invasion and metastasis by targeting tenascin C and
SOX4 in breast cancer [24]. miR-29c, which is downreg-
ulated in nasopharyngeal carcinomas, targets several
genes that encode extracellular matrix proteins, includ-
ing multiple collagens and laminin γ1; these proteins are
associated with increased tumor invasion and metastasis
[25]. Therefore, miRNAs are believed to be coordinated
regulators of the remodeling of the extracellular matrix
during cancer cell invasion.
Many cancer cells undergo epithelial-mesenchymal
transition (EMT) to achieve enhanced motility and to
gain resistance to apoptosis; however, some cancer cells
might undergo collective migration independent of an
EMT program. The miR-34/SNAIL and miR-200/ZEB
mutual-inhibition feedback circuits contribute to the
regulation of epithelial-hybrid-mesenchymal fate deter-
mination and collective migration [26]. miR-21 is involved
in epithelial collective cell migration [27]. Recently, it was
shown that miR-124 directly regulates the stability and
translation of integrin β1 mRNA in order to modulate the
intercellular adhesion of the leading cells in tumors during
collective invasion [28]. However, little is known at present
regarding the role of miRNAs in the regulation of collect-
ive migration in the tumor metastatic cascade.
miRNAs and intravasation
To disseminate to distant sites, invasive cancer cells
must enter the circulatory or lymphatic systems or travel
across the body cavities. The destruction of vascular
endothelial barriers is a critical step for cancer cell intra-
vasation. miR-105 is secreted by metastatic breast cancer
cells and promotes metastasis by direct targeting of the
tight junction protein ZO-1, which destroys vascular
endothelial barriers [29]. Compared with normal breast
tissues, miR-21 is highly expressed in breast tumors and
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and reduced survival time. The suppression of miR-21
significantly reduces the invasion and lung metastasis of
breast cancer cells by targeting TPM1, PDCD4 and
Maspin [30]. In addition to the promotion of cell inva-
sion and proliferation, miR-21 can enhance colorectal
cancer cell intravasation by binding to the 3′-UTR of
PDCD4. The downregulation of miR-21 in colorectal
cancer cells inhibits invasion, intravasation and lung
metastasis [31]. miR-182 is significantly overexpressed
in mouse sarcomas that metastasize to the lungs. miR-
182 deletion decreases circulating tumor cells, whereas
miR-182 overexpression increases circulating tumor
cells, which indicates that miR-182 promotes the entry
of cancer cells into the circulation [32].
The expression of members of the miR-520c/miR-373
family negatively correlates with lymph node metastasis,
specifically in ER-negative breast cancers. The miR-
520c/miR-373 family inhibits cell invasion in vitro as
well as the intravasation of breast cancer cells in vivo
and plays a tumor-suppressive role in ER-negative breast
cancers via the regulation of the NF-κB and TGF-β path-
ways [33]. RKIP inhibits breast cancer cell intravasation
and bone metastasis in mice in part through a signaling
cascade that involves MAPK, Myc, LIN28, let-7 and
downstream let-7 targets, which indicates that let-7 may
be involved in RKIP-inhibited cell intravasation [34].
These findings have opened new avenues in our under-
standing of the roles of miRNAs in the regulation of
cancer cell intravasation during tumor metastasis.
miRNAs and the systemic circulation
Anoikis is a special form of programmed cell death that
occurs when normal cells detach from the extracellular
matrix or from cell–cell anchors and are maintained in
suspension. Under normal circumstances, anoikis prevents
the attachment of these detached cells to an inappropriate
extracellular matrix and prevents the colonization of these
cells outside of their usual anatomical site. After they enter
the circulation, some cancer cells are destroyed in the
bloodstream by shear stress and by anoikis. Therefore,
DTCs must still overcome detachment, evade immune at-
tack and survive the sheer forces that they encounter in
the circulation. Several lines of evidence have indicated
that p53 and various other proteins play important roles
in anoikis, which is triggered by a lack of adhesion;
however, the specific miRNAs that regulate anoikis in
the systemic circulation are unknown.
The level of miR-296-3p is much higher in highly meta-
static human prostate cancer cells than in non-metastatic
cells. The knockdown of miR-296-3p in metastatic human
prostate cancer cells reduces their resistance to natural
killer (NK) cells, whereas the ectopic overexpression of
miR-296-3p in non-metastatic prostate cancer cellsenhances the tolerance of these cells to NK cells. miR-
296-3p promotes prostate cancer metastasis through an
augmentation of the survival of NK cell-resistant circulat-
ing tumor cells by targeting ICAM-1 [35]. miR-148b is
downregulated in aggressive breast tumors and inhibits
multiple steps of tumor progression via the regulation of
invasion, resistance to anoikis, extravasation, metastatic
colonization in lung and chemotherapeutic response [36].
Although several miRNAs contribute to cell survival and
help cells to overcome the shear stress and immune
attack, little is known in regards to the molecular
mechanisms of miRNAs in the systemic circulation of
cancer cells.
miRNAs and extravasation
For blood vessel-borne metastasis, cancer cells must ar-
rest or adhere to the endothelial lining and then undergo
extravasation. As a potent regulator of ZO-1, miR-105
can be expressed and secreted by metastatic breast can-
cer cells, which can then disrupt the tight junctions of
endothelial cells. In endothelial monolayers, exosomal
miR-105, which is secreted by breast cancer cells, not
only destroys the endothelial barriers in primary sites
but also disrupts the tight junctions of endothelial cells
in secondary organs, which allows cells to extravasate.
miR-105 overexpression in non-metastatic cancer cells
promotes vascular permeability and metastasis to distant
sites, whereas miR-105 inhibition in highly metastatic
tumors alleviates these effects [29]. Thus, miR-105 can
efficiently destroy the integrity of vascular endothelial
barriers to promote metastasis. miR-155 is frequently
highly expressed in several types of human cancers.
miR-155-expressing breast tumors are associated with
an aggressive malignant phenotype and with poor prog-
nosis [37]. Interestingly, the loss of miR-155 reduced
central nervous system extravasation of systemic tracers
in mice. Moreover, miR-155 negatively regulates the
function of the brain endothelial barrier by through the
targeting of the cell-cell complex molecules annexin-2
and claudin-1 and the focal adhesion components
DOCK-1 and syntenin-1 [38], which indicates that miR-
155 may promote cancer cell extravasation during the
process of tumor metastasis. miR-214 expression is
deregulated in several human tumors. It suppresses cell
migration and invasion in vitro and inhibits the metasta-
sis of colorectal cancer to the liver in vivo by targeting
FGFR1 [39]. In contrast, miR-214 promotes melanoma
metastasis through an enhancement of extravasation
[40]. miR-214 overexpression in melanoma cells not only
promotes cell migration, invasion and resistance to
anoikis in vitro but also promotes extravasation and the
formation of lung metastasis in vivo [41].
The expression of miR-31 expression is inversely cor-
related with metastasis in patients with breast cancer.
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local invasion, extravasation, initial survival in distant
tissues and distant colony formation. The shRNA-
mediated concurrent suppression of ITGA5, RDX and
RhoA is sufficient to phenocopy the influences of miR-
31 on local invasion, early post-intravasation events and
metastatic colonization in vivo [42]. A recent report
demonstrates that overexpression of miR-25 in highly
metastatic human prostate cancer cells attenuates me-
tastasis via the inhibition of extravasation in vivo by dir-
ect targeting of αv- and α6-integrins [43]. These findings
suggest that miRNAs can regulate tumor metastasis
through the modulation of extravasation.
miRNAs and metastatic colonization
Metastatic colonization is the key rate-limiting step in
the tumor metastasis cascade. The overexpression of
miR-200 s correlates with an increased risk of metastasis
in breast cancer and augments metastatic colonization
in mice partly through the direct targeting of Sec23a
[44]. Breast cancer patients with metastasis have a high
level of circulating miR-122. Breast cancer-cell-secreted
miR-122 promotes metastatic colonization in the brain
and lungs of mice and inhibits glucose uptake by niche
cells through the targeting of pyruvate kinase. This
process results in an increase in glucose that is available
to the cancer cells that are undergoing metastasis in pre-
metastatic niches [45].
Profile analyses have revealed that the level of miR-149
is extremely low in basal breast cancer. The expression
of miR-149 significantly inhibits basal-like breast cancer
cell migration and invasion in vitro and impairs lung
colonization in vivo [46]. For successful metastatic
colonization in the liver, DTCs must settle and adapt to
the unfavorable microenvironment of the liver paren-
chyma and resume proliferation. The former metastatic
steps are relatively easy to overcome because of direct
blood circulation via portal veins and because of the por-
ous property of the liver sinusoids. miR-493 inhibits the
settlement of colon cancer cells that have metastasized
in the liver parenchyma and promotes the death of these
cells by targeting IGF1R [47]. miR-148a is abundant in
the liver but is dramatically downregulated in HCC tis-
sues. The restoration of miR-148a expression in hepa-
toma cells markedly inhibits their migration in vitro
and their pulmonary metastatic colonization in vivo
[48]. Collectively, these findings demonstrate that many
miRNAs are involved in the regulation of metastatic
colonization.
Functions of miRNAs in EMT during tumor metastasis
EMT is the critical program that is used by DTCs for inva-
sion and metastasis. In patients with breast cancer, the
miR-9 levels in primary tumors from patients withdiagnosed metastases are markedly upregulated compared
with those from metastasis-free patients. miR-9 can pro-
mote the motility and invasiveness of breast cancer cells
by targeting CDH1, the E-cadherin-encoding messenger
RNA [49]. A high level of miR-155 is frequently observed
in invasive breast cancer tissues. miR-155 knockdown in-
hibits TGF-β-induced EMT, dissolution of tight junction,
cell migration and invasion [50]. Patients with gallbladder
carcinoma with higher miR-20a levels exhibit worse over-
all survival than those with lower miR-20a levels. miR-20a
is closely correlated with local invasion, distant metastasis,
and poor prognosis in patients with gallbladder carcinoma.
The overexpression of miR-20a in gallbladder carcinoma
cells induces EMT and promotes metastasis via the direct
inhibition of Smad7 [51].
miR-200 family members are important markers of
epithelial cells and are critical master regulators of EMT.
Under normal conditions, miR-200 can inhibit the ex-
pression of ZEB1 and ZEB2, which promotes an epithe-
lial phenotype and cell adhesion. However, ZEB1 and
ZEB2 can be activated by the contextual signals within
the tumor microenvironment and can suppress the ex-
pression of their own suppressor, miR-200, to promote
EMT, invasion and metastasis [52, 53]. The level of miR-
203 is extremely low in highly metastatic breast cancer
cells, and the overexpression of miR-203 in these cells
suppresses cell invasion in vitro and metastatic
colonization of the lung in vivo via the targeting of
SNAI2. Moreover, miR-203 and SNAI2 inhibit the ex-
pression of each other through a negative feedback loop,
which modulates EMT and metastasis [54]. miR-124 is
frequently downregulated in HCC tissues and is nega-
tively correlated with a poor prognostic phenotype in pa-
tients with HCC. The overexpression of miR-124 in
HCC cells inhibits EMT and the formation of stress fi-
bers (i.e., filopodia and lamellipodia) in vitro and sup-
presses intrahepatic and pulmonary metastasis in vivo,
most likely by targeting ROCK2 and EZH2 [55]. The ex-
pression of miR-612 in patients with HCC is inversely
correlated with tumor size, stage, EMT and metastasis.
miR-612 contributes to both the initial and final steps of
the metastatic cascade by inhibiting local invasion and
distant metastatic colonization [56]. miR-125a is a re-
cently identified regulator of myeloid malignancies that
targets WT1. miR-125a knockout mice develop myelopro-
liferative disorders and exhibit urogenital abnormalities
[57]. Moreover, miR-125a can inhibit EMT in ovarian can-
cer cells by targeting ARID3B [58]. Therefore, miRNAs
are critical coordinating regulators of EMT during tumor
metastasis.
Only a small subset of DTCs has the potential to initi-
ate metastatic growth in a new tissue environment [22].
Once they become established in a new tissue environ-
ment, metastatic cancer cells revert to a non-metastatic
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tion (MET). Twist1 can induce EMT to facilitate breast
cancer cell intravasation into the circulation and the
subsequent dissemination of these cells into the lungs.
However, for DTCs to proliferate and form metastases at
distant sites, Twist1 must be turned off to allow MET to
proceed [59]. Interestingly, Twist1 can promote the ex-
pression of miR-10b by directly binding to the promoter
of miR-10b [11], which indicates that miR-10b may
affect the invasion, intravasation, circulation, extravasa-
tion and metastatic colonization of breast cancer cells.
Recently, miR-424 has been shown to be positively asso-
ciated with EMT-like phenotypes and with Twist1/2 ex-
pression. miR-424 is highly expressed in primary breast
tumors compared with matched normal breast tissues;
however, miR-424 expression is decreased in metastases
compared with matched primary breast tumors [60].
These findings demonstrate that EMT and/or MET are
critical programs used by cancer cells for metastasis.
Functions of miRNAs with respect to cancer stem cells in
tumor metastasis
Cancer stem cells (CSCs) are a sub-population of can-
cer cells that are thought to be responsible for tumor
initiation, metastasis, resistance to therapy and relapse
[22, 61, 62]. Aberrant expression of miRNAs may play
a critical role in the regulation of the characteristics
and functions of CSCs in tumor metastasis. The im-
pairment of the miRNA biogenesis gene DICER1 in
colorectal cancer cells promotes tumor initiation and
metastasis by endowing colorectal cancer cells with
stem cell properties and EMT phenotypes [63]. miR-22
overexpression is associated with poor clinical out-
comes of breast cancer patients and promotes EMT, in-
vasiveness, stemness and metastasis [64]. A high level
of miR-199a correlates with poor survival in patients
with breast cancer. Mesenchymal stem/stromal cells
promote the aberrant expression of miR-199a in breast
cancer cells in a contact-dependent manner. Subse-
quently, miR-199a inhibits the expression of FOXP2
and endows breast cancer cells with enhanced CSC
properties [65]. miR-9 is highly expressed in metastatic
human primary squamous cell carcinoma. A high level
of miR-9 enhances the expansion and metastasis of
squamous cell carcinoma CSCs [66]. Increased miR-
133a is significantly correlated with poor prognosis in
patients with osteosarcoma. The silencing of miR-133a
by locked nucleic acids (LNAs) inhibits the invasiveness
of CSCs that express high levels of CD133. The admin-
istration of LNAs with chemotherapy synergistically in-
hibits lung metastasis and prolongs the survival of
osteosarcoma-bearing mice [67].
As a key negative regulator of prostate CSCs, miR-34a
suppresses prostate CSCs and metastasis by directlytargeting CD44 [68]. miR-7 is downregulated in breast
CSCs. The overexpression of miR-7 can suppress cell in-
vasion and metastasis through a decrease in the breast
CSC population and by a partial reversal of the EMT
phenotype in breast cancer cells by targeting SETDB1
[69]. Interestingly, by targeting KLF4, miR-7 overexpres-
sion inhibits the ability of breast CSCs to metastasize to
the brain [70]. We recently demonstrated that the ex-
pression level of miR-33b is extremely low in human
breast cancer samples and in highly metastatic breast
cancer cell lines. Moreover, miR-33b can reduce the
stemness and inhibit the metastasis of breast cancer cells
to the lungs through the regulation of HMGA2, SALL4
and Twist1 [71]. Therefore, miRNAs are critical players
in the modulation of the stemness of DTCs in the meta-
static cascade.
Functions of miRNAs in the metastatic microenvironment
DTCs at distant sites must evade immune attack or recruit
immune/inflammatory cells or other stromal cells and
their secreted factors to assist them so that they can adapt
and remodel the metastatic microenvironment and
complete the subsequent proliferation and colonization
steps of the metastatic cascade [2, 10].
Portal vein tumor thrombus (PVTT) is highly related to
poor prognosis in individuals with HCC. miR-34a can de-
crease the production of the chemokine CCL22, which re-
cruits regulatory T cells to facilitate immune escape.
Moreover, miR-34a expression can be inhibited by TGF-β.
Interestingly, HBV infection and the activity of the TGF-
β-miR-34a-CCL22 axis predispose HCC patients to the
development of PVTT, possibly through the formation of
an immune-supportive microenvironment that favors the
colonization of disseminated HCC cells in the portal ven-
ous system [72]. Recently, miR-34a was identified as a
novel suppressor of osteoclastogenesis, bone resorption
and the bone metastatic niche. The metastasis of breast
and skin cancers to bone is diminished in osteoclastic
miR-34a transgenic mice but is exacerbated in miR-34a
knockout and heterozygous mice. In addition, miR-34a
nanoparticle treatment can attenuate the metastasis of
breast and skin cancers to bone. Moreover, miR-34a is
downregulated during osteoclast differentiation and is a
newly identified suppressor of osteoclastogenesis and bone
resorption. Therefore, osteoclastic miR-34a can effectively
inhibit malignant progression by disturbing the bone
metastatic niche [73]. In addition, the levels of two other
osteoclast miRNAs, miR-16 and miR-378, are increased in
bone lesions and in serum samples from patients with
bone metastasis and correlate with the bone metastasis
burden [74]. Thus, these osteoclastic miRNAs are poten-
tial biomarkers and therapeutic targets of bone metastasis.
miR-155 is involved in the development and function
of immune cells [75]. The knockdown of miR-155 in the
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promotes tumor growth by impairing the activation of
tumor-associated macrophages [76]. Bone marrow that
lacks miR-155 significantly promotes lung metastasis but
does not have a substantial effect on primary tumor
growth. The expression of miR-155 in host immune cells
inhibits solid tumor metastasis by regulating the recruit-
ment and polarization of bone marrow-derived macro-
phages [77]. miR-155 deficiency promotes the growth of
melanoma and Lewis lung carcinoma tumors by enhan-
cing the recruitment of myeloid-derived suppressor cells
(MDSCs) to the tumor microenvironment [78]. However,
a high level of miR-155 in leukemia cells correlates with
aggressive disease in patients with chronic lymphocytic
leukemia (CLL). miR-155 enhances cell sensitivity to
B-cell receptor ligation, which indicates that miR-155 is
involved in the regulation of the tumor microenvironment
of CLL [79]. Recently, the inhibition of miR-155 by
antisense oligomers was used for cancer therapy that
was targeted to the tumor microenvironment in a
mouse model of lymphoma [80]. MDSCs potently inhibit
anti-tumor immune responses and contribute to the for-
mation of a metastatic microenvironment that favors
tumor metastasis. The expression of miR-494 promotes
the accumulation of MDSCs in tumor tissues. The knock-
down of miR-494 reverses the function of MDSCs in tu-
mors and suppresses tumor growth and breast cancer cell
metastasis in vivo [81]. MDSCs induce the expression of
miR-101 in ovarian cancer cells, which subsequently aug-
ments the stemness of cancer cells and enhances their
tumorigenic and metastatic potential [82].
Enhanced endothelial recruitment capacity is also a key
feature of metastatic breast cancer cell populations. The
silencing of miR-126 in breast cancer cells significantly
promotes metastatic colonization in multiple organs, such
as the lung, brain, bone and liver, via the enhancement of
endothelial recruitment. Endogenous miR-126 can inhibit
endothelial recruitment, metastatic angiogenesis and
metastatic colonization of distant sites by coordinately tar-
geting IGFBP2, PITPNC1 and MERTK [83]. Interestingly,
miR-126 and miR-126* target SDF-1α to suppress breast
cancer metastasis through the inhibition of the recruit-
ment of mesenchymal stem cells and inflammatory mono-
cytes [84]. Therefore, the recruitment of endothelial cells,
mesenchymal stem cells and inflammatory monocytes,
which is regulated by miR-126 and/or miR-126*, may pro-
vide incipient metastases with a critical microenvironmen-
tal cue that promotes the efficiency of metastatic initiation
and results in enhanced metastatic colonization.
DTCs exist in a dormant state when they are in a hostile
metastatic microenvironment but may switch from dor-
mancy into proliferative metastatic growth in a supportive
microenvironment. Tumor dormancy in metastatic sites
can be regulated by intracellular signaling pathways andby extracellular microenvironmental cues [85, 86]. The
exosomal transfer of miR-23b from bone marrow mes-
enchymal stem cells can promote breast cancer cell
dormancy in a metastatic niche, as miR-23b targets
MARCKS [87]. The CXCL12-specific miRNAs, including
miR-127, −197, −222 and −223, which are transported
from bone marrow-derived stromal cells to breast cancer
cells via gap junctions or stromal-derived exosomes, pro-
mote breast cancer cell quiescence by a decrease in
CXCL12 levels. This finding indicates that the transfer of
miRNAs from bone marrow stroma to breast cancer cells
can regulate the dormancy of metastatic breast cancer
cells in the bone marrow [88]. However, to date, few
miRNAs that maintain the dormant or active state of
DTCs have been identified.
miRNAs as diagnostic and prognostic biomarkers and
therapeutic targets for tumor metastasis
miRNAs that are strongly associated with metastatic
phenotypes may be useful as diagnostic or prognostic
markers of metastasis. The overexpression of miR-103
and miR-107 in a mouse model of colorectal cancer was
shown to promote local invasion and liver metastasis by
targeting DAPK and KLF4. The signature of a high miR-
103/107, low DAPK and low KLF4 expression profile
correlates with the extent of lymph node and distant
metastasis in patients with colorectal cancer. Thus, miR-
103 and miR-107 can be used as prognostic markers for
metastatic recurrence and for poor survival in patients
with colorectal cancer [89]. The expression of miR-340
is significantly decreased in bone marrow cells of colorec-
tal cancer patients with liver metastasis. Thus, miR-340
may be a novel prognostic factor and a therapeutic target
for colorectal cancer [90]. The overexpression of miR-630
in breast cancer cells that are resistant to HER-targeted
drugs significantly restores the efficacy of those drugs (e.g.,
lapatinib, neratinib and afatinib), which indicates that
miR-630 can be used as a diagnostic and predictive marker
to gauge the treatment response to HER-targeted drugs
[91]. Further research in regards to miRNAs will facilitate
the accurate and early identification of DTCs, will provide
tractable targets for the monitoring of minimal residual
disease and will help predict responses to treatment that is
aimed at the prevention of metastasis.
The overexpression and inhibition of miRNA using
miRNA mimics and inhibitors, respectively, might be use-
ful for the treatment of tumor metastasis. miR-1908, miR-
199a-5p and miR-199a-3p promote invasion, angiogenesis
and colonization in the case of melanoma by the conver-
gent targeting of ApoE. The therapeutic delivery of locked
nucleic acids to silence these aberrantly expressed miR-
NAs significantly inhibits the metastasis of melanoma to
multiple organs. Therefore, multiple prognostic miRNAs
with synergistic combinatorial therapeutic potential can be
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carry a large number of DTCs in their circulation, bone
marrow and other distant sites at the time of their initial
cancer diagnosis. Therefore, effective anti-metastatic treat-
ment must inhibit the survival and proliferation of metas-
tases that are already established. The induction of miR-31
in already-established metastases triggers pulmonary
metastatic regression and extends survival, whereas the
acute activation of miR-31 does not affect primary mam-
mary tumor growth. This finding indicates that the restor-
ation of miR-31 function may be used to specifically target
metastatic disease [93]. The plasma level of miR-101 is
higher in HCC patients without distant metastases com-
pared with those with distant metastases. In an animal
model of HCC, the delivery of lentivirus-mediated miR-Fig. 1 The roles of microRNAs in the regulation of tumor metastasis. Tumo
To disseminate to distant sites, tumor cells detach from their primary sites
For blood vessel-borne metastasis, disseminated tumor cells (DTCs) intravas
at distant organ sites, DTCs must extravasate from the blood and adapt to
micrometastases. Finally, only a small subset of micrometastases eventual
miRNAs can regulate the expression of multiple target genes and can mo
intravasation, resistance to anoikis, extravasation and metastatic colonizat
and the tumor microenvironment. miRNAs may act as positive regulators (pur
ECM, extracellular matrix; CSC, cancer stem cell101 inhibits HCC growth, intrahepatic metastasis and
distant metastasis [94]. The administration of miR-10b
antagomirs in mice with highly metastatic cells signifi-
cantly inhibits lung metastases but does not affect primary
mammary tumor growth [95]. Thus, miRNA mimics and
inhibitors are potential candidates for the targeting of
tumor metastasis.
Conclusions and future perspectives
Current evidence has demonstrated that various miRNAs
play critical roles in the coordination of tumor cell in-
vasion, intravasation, survival, extravasation and/or
colonization, as well as EMT, stemness, dormancy and
the metastatic microenvironment (Fig. 1) (Table 1).
Although metastasis-related miRNAs have opened ar metastasis is a complex process that is composed of multiple steps.
by local migration, invasion and penetration of the stromal cell layers.
ate into blood vessels and survive in the circulation. After they arrive
the new tissue microenvironments, where only a few DTCs form
ly becomes detectable macrometastases. During this metastatic cascade,
dulate multiple tumor cell phenotypes, such as motility, invasion,
ion as well as epithelial-mesenchymal transition, cell stemness, dormancy
ple) or negative regulators (blue) in the regulation of tumor metastasis.
Table 1 Functions of microRNAs in tumor metastasis
microRNA Function in tumor metastasis Targets and putative targets References
miR-10b Promotes cell migration, invasion and metastasis TP53, PAX6, NOTCH1, HOXD10 [11, 12]
miR-19a/b Promotes gastric cancer cell migration, invasion and metastasis MXD1 [13]
miR-135b Promotes cell migration, invasion and metastasis LATS2, β-TrCP, NDR2, LZTS1 [14]
miR-362-5p Promotes cell proliferation, migration and invasion in vitro and tumor growth
and metastasis in vivo
CYLD [15]
miR-34a Inhibits cell migration, invasion and lung metastasis of breast cancer cells;
suppresses prostate CSCs and metastasis; decreases the production of the
chemokine CCL22; disturbs the bone metastatic niche
Fra-1, CD44, CCL22, Tgif2 [16, 68, 72, 73]
miR-34c Inhibits cell migration, invasion and lung metastasis of breast cancer cells Fra-1 [16]
miR-135a Inhibits prostate cancer cell migration and invasion ROCK1, ROCK2 [17]
miR-137 Reduces the invasiveness of colorectal cancer cells FMNL2 [18]
miR-145 Attenuates gastric cancer cell migratory and invasive abilities in vitro and
suppresses the metastatic cascade in vivo; inhibits the invasion and metastasis of
neuroblastoma cells
N-cadherin, HIF-2α [19, 20]
miR-1 Affects the cellular organization of F-actin and impairs tumor cell invasion and
filopodia formation
FN1, LASP1, XPO6 [21]
miR-335 Suppresses cell migration, invasion and metastasis Tenascin C, SOX4 [24]
miR-29c Inhibits tumor invasion and metastasis Collagens, Laminin γ1 [25]
miR-21 Promotes epithelial collective cell migration, invasion and lung metastasis;
enhances colorectal cancer cell intravasation
TPM1, PDCD4, Maspin, PDCD4 [27, 30, 31]
miR-124 Modulates the intercellular adhesion of leading cells; inhibits EMT in vitro and
suppresses intrahepatic and pulmonary metastasis in vivo
Integrin β1, ROCK2, EZH2 [28, 55]
miR-105 Destroys the integrity of vascular endothelial barriers to promote metastasis ZO-1 [29]
miR-182 Promotes cancer cell intravasation into the circulation Mtss1, Pai1, Rsu1, Timp1 [32]
miR-520c/373 Inhibits cell invasion in vitro and the intravasation of breast cancer cells in vivo RELA, TGFBR2 [33]
let-7 Inhibits bone metastasis of breast cancer cells HMGA2, Snail [34]
miR-296-3p Promotes prostate cancer cell survival ICAM-1 [35]
miR-148b Inhibits multiple steps of tumor progression via the regulation of invasion,





miR-155 Negatively regulates the function of the brain endothelial barrier; promotes
TGF-β-induced EMT, tight junction dissolution, cell migration and invasion.
Suppresses tumor growth via the regulation of the tumor microenvironment
Annexin-2, Claudin-1, DOCK-1,
Syntenin-1, c-Maf, Pu.1, Ship1,
C/EBPβ, HIF-1α
[38, 50, 76–78]
miR-214 Suppresses cell migration and invasion in vitro and inhibits liver metastasis of
colorectal cancer cells in vivo but promotes migration, invasion and resistance to
anoikis of melanoma cells in vitro and the extravasation and lung metastasis
formation in vivo
FGFR1, TFAP2C [39–41]
miR-31 Represses local invasion, extravasation and initial survival in distant tissues and
distant metastatic colonization
ITGA5, RDX, RhoA [42]
miR-25 Inhibits extravasation of prostate cancer cells in vivo αv- and α6-integrins [43]
miR-200s Inhibits EMT but promotes metastatic colonization Sec23a, ZEB1, ZEB2 [44, 52, 53]
miR-122 Promotes metastatic colonization of breast cancer cells PKM2 [45]
miR-149 Inhibits basal-like breast cancer cell migration and invasion in vitro and impairs
lung colonization in vivo
Rap1a, Rap1b [46]
miR-493 Inhibits the settlement of metastasized colon cancer cells in the liver; promotes the
death of colon cancer cells
IGF1R [47]
miR-148a Inhibits hepatoma cell migration in vitro and pulmonary metastatic colonization
in vivo
Met [48]
miR-9 Promotes breast cancer cell motility and invasiveness; enhances squamous cell
carcinoma CSC expansion and metastasis
CDH1, α-catenin [49, 66]
miR-20a Induces EMT and promotes metastasis Smad7 [51]
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Table 1 Functions of microRNAs in tumor metastasis (Continued)
miR-203 Suppresses cell invasion and EMT in vitro and lung metastatic colonization in vivo SNAI2 [54]
miR-612 Inhibits local invasion and distant metastatic colonization Akt2 [56]
miR-125a Inhibits EMT of ovarian cancer cells ARID3B [58]
miR-424 Promotes EMT TGFBR3 [60]
miR-22 Promotes EMT, invasiveness, stemness and metastasis TET1, TET2, TET3 [64]
miR-199a Endows breast cancer cells with enhanced CSC properties; promotes invasion,
angiogenesis and colonization in the case of melanoma
FOXP2, ApoE [65, 92]
miR-133a Promotes invasion of CSCs that express high levels of CD133 SGMS2, UBA2, SNX30, ANXA2 [67]
miR-7 Suppresses cell invasion and metastasis; inhibits the ability of breast CSCs to
metastasize to the brain
SETDB1, KLF4 [69, 70]
miR-33b Inhibits the stemness and lung metastasis of breast cancer cells HMGA2, SALL4, Twist1 [71]
miR-494 Promotes the accumulation of MDSCs in tumor tissues PTEN [81]
miR-101 Augments cancer cell stemness and enhances the tumorigenic and metastatic
potential of cancer cells; inhibits HCC growth, intrahepatic metastasis and distant
metastasis
CtBP2, ROCK2 [82, 94]
miR-126 Inhibits endothelial recruitment, metastatic angiogenesis and metastatic




miR-126* Suppresses breast cancer metastasis via the inhibition of the recruitment of
mesenchymal stem cells and inflammatory monocytes
SDF-1α [84]
miR-23b Promotes breast cancer cell dormancy in a metastatic niche MARCKS [87]
miR-127/197/
222/223
Promotes breast cancer cell quiescence CXCL12 [88]
miR-103/107 Promotes local invasion and liver metastasis DAPK, KLF4 [89]
Zhou et al. Cell & Bioscience  (2015) 5:32 Page 9 of 12new field of research with respect to tumor metastasis,
research on the functions and mechanisms of miRNAs
in tumor metastasis has only recently begun.
Interestingly, miRNAs in vesicles secreted from highly
metastatic tumor cells can be internalized by weakly
metastatic cells or stromal cells and subsequently influ-
ence the functions of these cells. Conversely, some miR-
NAs that are secreted from stromal cells can modulate
the metastatic ability of DTCs. Thus, secretory miRNAs
provide versatile communication between cancer cells
and stromal cells and regulate the capacity for tumor
growth at metastatic lesions. Moreover, the context-
dependent roles of miRNAs in the metastatic cascade
often involve multiple regulatory loops. The altered ex-
pression of one miRNA can regulate the expression of
multiple target genes and modulate multiple cancer cell
phenotypes, such as motility, invasion, resistance to
anoikis and metastatic colonization. However, little is
known about the roles of miRNAs in the regulation of
DTC intravasation, circulation and extravasation. In
addition, compared with conventional metastasis-related
transcription factors, in most cases, miRNAs do not
function as master regulators in the hierarchy of gene
regulators. miRNAs may behave as critical tuners of
transcriptional programs through the coordination of
regulatory signaling networks that allow cells to adapt to
microenvironmental and intracellular stresses duringtumor metastasis. Comparisons of miRNA expression
profiles of metastatic tumors in secondary sites with
those of corresponding normal tissues and primary tu-
mors have demonstrated that alterations in miRNA ex-
pression profiles can serve as phenotypic signatures of
particular types of tumor metastasis and of specific steps
in the tumor metastatic cascade. Therefore, miRNA ex-
pression profiling to screen for miRNAs that may serve
as diagnostic or prognostic biomarkers or as therapeutic
targets for tumor metastasis has great potential. How-
ever, much research is still needed for the development
of effective miRNA-targeted therapies. A complete and
accurate understanding of the molecular mechanisms
of miRNAs in tumor metastasis will reveal invaluable
diagnostic and prognostic biomarkers as well as poten-
tial targets for the therapeutic intervention of tumor
metastasis.
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